MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
July 09 2024 - 4:05PM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and
innovative bioprocessing applications, today announced that it will
release financial results for the second quarter 2024 after the
U.S. market close on Tuesday, August 6th, 2024. Company management
will host a conference call to discuss financial results at 4:30
p.m. Eastern Time.
Earnings Conference Call DetailsInvestors
interested in listening to the conference call are required to
register online. It is recommended to register at least a day in
advance. A live and archived webcast of the event will be available
on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
About MaxCyteAt MaxCyte, we pursue
cell engineering excellence to maximize the potential of cells to
improve patients’ lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today’s
processes to innovate tomorrow’s solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx ™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn.
MaxCyte Contacts: US IR
Adviser Gilmartin Group David
Deuchler, CFA +1
415-937-5400 ir@maxcyte.com
US Media Relations Spectrum
Seismic Collaborative Valerie Enes +1
408-497-8568 venes@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker Panmure LiberumEmma Earl / Freddy
Crossley Corporate Broking Rupert Dearden +44 (0)20
7886 2500
UK IR Adviser ICR
ConsiliumMary-Jane Elliott Chris Welsh +44
(0)203 709 5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Aug 2023 to Aug 2024